Skip to main content

$1.23 -0.02 (-1.21%)

High

$1.29

Low

$1.18

Trades

155

Turnover

$303,224

Volume

249,053
30 June 2023 at 4:10pm
Register to track RAC and receive email alerts.
Subject
RAC Ann: Contract to Commence Phase 2 Extramedullary AML Trial

RAC Ann: Race appoints Professor Michael Kelso as Principal Scientist

RAC Ann: Appendix 3Y - Mary Harney

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Appendix 3Y - Phillip Lynch - corrected

RAC Ann: Appendix 3Y - Phillip Lynch

RAC Ann: Appendix 3Y - Dr John Cullity

RAC Ann: Lapse of Unlisted Options

RAC Ann: Replacement Announcement - Bonus Options Issued

RAC Ann: Bonus Options Issued

RAC Ann: Appendix 2A

RAC Ann: Appendix 2A

RAC Ann: Appendix 2A

RAC Ann: Bisantrene Preclinical Drug Study Published

RAC Ann: Bonus Issue of Options - Letter to Ineligible Shareholders

RAC Ann: Bonus Issue of Options - Letter to Eligible Shareholders

RAC Ann: Proposed issue of Securities - RAC

RAC Ann: Prospectus

RAC Ann: Race investor briefing & updated presentation

RAC Ann: Placement closes oversubscribed-Bonus Option Issue launched

RAC Ann: Trading Halt

RAC Ann: Race Initiates Heart Safety Preclinical Study for Bisantrene

RAC Ann: Quarterly Activity Report & Appendix 4C

RAC Ann: Change in substantial holding

RAC Ann: Cleansing Notice

RAC Ann: Appendix 2A

RAC Ann: Race appoints Dr David Fuller Chief Medical Officer

RAC Ann: City of Hope Professor Jianjun Chen joins Race's SAB

RAC Ann: Second independent study shows Bisantrene inhibits FTO

RAC Ann: Cleansing Notice

RAC Ann: Appendix 2A

RAC Ann: Cleansing Notice

RAC Ann: Appendix 2A

RAC Ann: Race Strategic Update March 2021

RAC Ann: Race Initiates Extramedullary AML Preclinical Study

RAC Ann: Race Initiates FTO Directed Kidney Cancer Preclinical Study

RAC Ann: Race Initiates FTO Melanoma Preclinical Study

RAC Ann: Change in substantial holding

RAC Ann: Change in substantial holding

RAC Ann: S&P DJI Announces March 2021 Quarterly Rebalance

RAC Ann: Appendix 3Y - Mary Harney

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Change in substantial holding

RAC Ann: Cleansing Notice

RAC Ann: Appendix 2A

RAC Ann: Compelling Preclinical Breast Cancer Results

RAC Ann: Change in substantial holding

RAC Ann: Appendix 4D & Half-Year Financial Statements

RAC Ann: Change in substantial holding

RAC Ann: Positive Early Preclinical Ovarian Cancer Results

Register to track RAC and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
TLX